Precigen Announces Phase 1 Data For PRGN-3005 Autologous UltraCAR-T Cells Manufactured Overnight For Infusion Next Day To Advanced Stage Platinum Resistant Ovarian Cancer Patients At 2023 ASCO Annual Meeting
Portfolio Pulse from Benzinga Newsdesk
Precigen announced Phase 1 data for PRGN-3005 UltraCAR-T cells, an overnight-manufactured treatment for advanced stage platinum-resistant ovarian cancer patients, at the 2023 ASCO Annual Meeting.
June 05, 2023 | 8:09 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Precigen's announcement of positive Phase 1 data for PRGN-3005 UltraCAR-T cells may boost investor confidence in the company's potential for treating advanced ovarian cancer.
The announcement of positive Phase 1 data for PRGN-3005 UltraCAR-T cells indicates progress in Precigen's development of a treatment for advanced ovarian cancer. This news may increase investor confidence in the company's potential, leading to a short-term positive impact on PGEN's stock price.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100